珍宝岛 20260128 摘要 珍宝岛药业正从东北区域性业务模式转型为全国销售体系，构建院内和 院外完整销售渠道，旨在扩大客户群体，优化财务报表，改善现金流、 应收账款和存货管理。 公司计划通过增加经销代理商至 3,000 多家，覆盖约 10 万家终端医疗 机构，以提升集采品种销量，预计 2026 年销量将显著增长，一季度有 望看到中药制剂收入超过 2024 年总收入 19.38 亿元的成果。 珍宝岛药业战略重心转向华东地区，以安徽为中心布局江浙沪，通过地 域和渠道扩张实现增长，同时拓展线上电商和直播平台销售保健品，该 业务毛利率和净利润远超传统医药产品。 复方芩兰口服液和小儿热速清糖浆有望纳入国家基本用药目录，公司已 完成系统性评价并提交推荐函，通过珍宝岛医药贸易有限公司实现全国 化布局，覆盖医疗、基础及零售三大终端。 珍宝岛投资的特瑞思生物制剂公司 CD20 ADC 在治疗弥漫大 B 细胞淋 巴瘤（DLBCL）的临床二期试验中显示显著疗效，中位总生存期 （OS）超过 24 个月，优于同类药物，预计今年完成二期临床后将在中 国申报上市。 Q&A 由于各省份响应速度不同，珍宝岛在销售终端的表现也有所差异。尽管 ...

证券日报网讯 1月27日，珍宝岛在互动平台回答投资者提问时表示，截至2025年12月18日公告披露，控 股股东累计质押公司股份比例为80.90%，未出现履约保障比例不足的情形。公司已与控股股东保持常 态化沟通，并密切关注质押风险变化。若触发相关风险，控股股东将严格按质押协议约定履行义务。公 司严格遵循信息披露规范，对于质押股份比例变动、风险应对进展等重大事项，均已通过临时公告及定 期报告履行披露义务。后续将持续通过法定信息披露渠道及时向投资者告知相关进展，保障信息透明 度。 （文章来源：证券日报） ...

证券日报网讯1月26日，珍宝岛（603567）在互动平台回答投资者提问时表示，公司严格遵守信息披露 法规，不存在应披露而未披露的重大事项，公司生产经营一切正常，各项业务正常开展。 ...

Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

Group 1 - The core point of the article is that Zhenbao Island (603567) reported its A-share shareholder count as of January 20, 2026, which stands at 24,589 households [1]

Group 1 - The core viewpoint of the news is that Zhenbao Island's financial performance has shown significant declines in revenue and net profit, indicating potential challenges for the company moving forward [2] - As of January 19, Zhenbao Island's stock price increased by 0.22%, with a trading volume of 50.28 million yuan and a net financing buy of -2.92 million yuan, reflecting a high level of financing balance [1] - The company has a total financing and securities lending balance of 302 million yuan, with the financing balance exceeding the 70th percentile of the past year, indicating a relatively high position in the market [1] Group 2 - For the period from January to September 2025, Zhenbao Island reported a revenue of 918 million yuan, a year-on-year decrease of 54.71%, and a net profit attributable to shareholders of -373 million yuan, a year-on-year decrease of 193.81% [2] - Zhenbao Island has distributed a total of 1.302 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3] - The number of shareholders as of September 30 is 20,900, a decrease of 2.72% from the previous period, while the average circulating shares per person increased by 2.80% to 44,969 shares [2]

Group 1 - The core viewpoint of the news is that Zhenbao Island's stock has experienced a decline, with significant trading activity and high financing levels, indicating potential investor concerns and market volatility [1][2]. Group 2 - On January 15, Zhenbao Island's stock fell by 3.07%, with a trading volume of 91.26 million yuan. The financing buy-in amount was 16.83 million yuan, while the financing repayment was 11.45 million yuan, resulting in a net financing buy of 5.39 million yuan. The total financing and securities balance reached 311 million yuan [1]. - The financing balance of Zhenbao Island is 310 million yuan, accounting for 3.48% of the circulating market value, which is above the 80th percentile level over the past year, indicating a high level of financing [1]. - On the short-selling side, Zhenbao Island had a short-selling repayment of 100 shares and a short-selling amount of 61,300 shares, with a selling amount of 581,100 yuan. The remaining short-selling volume was 97,500 shares, with a short-selling balance of 924,300 yuan, also above the 80th percentile level over the past year [1]. Group 3 - As of September 30, Zhenbao Island had 20,900 shareholders, a decrease of 2.72% from the previous period. The average circulating shares per person increased by 2.80% to 44,969 shares [2]. - For the period from January to September 2025, Zhenbao Island reported an operating income of 918 million yuan, a year-on-year decrease of 54.71%. The net profit attributable to the parent company was -373 million yuan, a year-on-year decrease of 193.81% [2]. Group 4 - Since its A-share listing, Zhenbao Island has distributed a total of 1.302 billion yuan in dividends, with 356 million yuan distributed over the past three years [3].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-004 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第一期可 交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码为"137171"，发行规模 9.1 亿元，债券 期限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的 临 2023-019 号公告。 "23 创 01EB"换股期为 2023 年 10 月 12 日至 2026 年 4 月 11 日。2025 年 ...

Core Viewpoint - The announcement from Zhenbao Island indicates a decrease in the shareholding percentage of its controlling shareholder, Heilongjiang Chuangda Group, due to the conversion of bonds into shares, impacting the ownership structure of the company [1] Group 1 - Zhenbao Island received a notification from its controlling shareholder, Heilongjiang Chuangda Group, regarding the issuance of non-public exchangeable bonds aimed at professional investors [1] - The bondholders converted a total of 8,842,536 shares between October 24, 2025, and January 12, 2026, leading to a passive decrease in Chuangda Group's shareholding [1] - As a result of the conversion, Chuangda Group's ownership in the company decreased from 57.92% to 56.98%, marking a change that touches the 1% scale integer [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-003 2.信息披露义务人信息 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动触及 1%刻度的提示性公告 黑龙江创达集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 57.92% | | | | 权益变动后合计比例 | 56.98% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | ...